The U.S. Food and Drug Administration (FDA) has cleared the Magnetom Lumina 3 Tesla (3T) magnetic resonance imaging (MRI) scanner from Siemens Healthineers.

XableCath Inc., announced that its XableCath blunt and abrasion tip catheters were cleared by the U.S. Food and Drug Administration (FDA) as peripheral crossing catheters. The catheters have been safely and successfully used to cross challenging lesions in both arterial chronic total occlusions (CTOs) and chronic obstructive venous lesions. The recent crossing FDA clearance adds to the previous clearances for endovascular support.

Thubrikar Aortic Valve Inc. announced the first human implant of the Optimum TAV using their transcatheter aortic valve implantation (TAVI) system.

LivaNova PLC announced the publication of three separate studies highlighting the performance of its sutureless aortic valve, Perceval.

The Medtronic Resolute Integrity drug-eluting stent is among the top three stents on the U.S. market. Outcomes for these stents are very similar, so the stents have largely become a commodity product purchased on price rather than clinical data. Stent advances and new stent technologies.
This is a closeup view of the Boston Scientific Synergy stent, which uses a bioresorbable drug-carrier polymer only on the abluminal side of the stent where it is needed. Clinical data shows lower rates of late-stent thrombosis using this technology. Stent advances and new technology.

There was a lot of hype and high hopes pinned on bioresorbable stent technologies as the way of the future two years ago. But the Absorb stent was not able to match the performance or outcomes of the current standard-of-care metallic drug-eluting stents (DES). Since the Absorb was pulled off the market in 2017, vendors have refocused efforts on refining metallic DES. 

The American College of Cardiology host the third Advancing the Cardiovascular Care of the Oncology Patient course in Washington on Jan. 25-27, 2019. The event brought together top experts in both cardiology and oncology to review new and relevant science in this rapidly evolving field.

Acutus Medical announced 12-month data from the UNCOVER-AF trial investigating the use of the AcQMap advanced cardiac imaging and mapping visualization system in persistent atrial fibrillation (AF) ablation procedures. Results presented at the 24th Annual AF Symposium, Jan. 24-26 in Boston, show the use of AcQMap resulted in 72.5 percent single-procedure freedom from AF at 12 months. Rigorous post-ablation monitoring showed 89.6 percent of the single-procedure patients experienced zero episodes of AF.

An example of multimodality image fusion with live angiography to enhance soft-tissue visualization during complex procedures. This example is from Siemen's new TrueFusion software released in 2018. Advances in angiography imaging.

There are a few recent trends in X-ray angiography imaging systems that hospitals should be aware of if they are looking for new or replacement technology. 

1. Technology to Lower Radiation Dose
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now